Paying for Patients

Paying for Patients How much should researchers pay clinical trial subjects? By Alla Katsnelson Related Articles 1 The wide range of payments, from $5 to $2,000 with a median of $155, also surprised her. "Everyone is worried so much about payment," says Grady, "but the amounts were pretty modest." The wide range of payments, from $5 to $2,000 with a median of $155, is surprising to Christine Grady. "Everyone is worried so much about payment, but the amounts were pre

Written byAlla Katsnelson
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

By Alla Katsnelson

1 The wide range of payments, from $5 to $2,000 with a median of $155, also surprised her. "Everyone is worried so much about payment," says Grady, "but the amounts were pretty modest."

The only thing that seemed clear was that "there doesn't seem to be a lot of clarity," she says.

Ethicists worry about payment because of two theoretical concerns. First, money may tempt people to agree to take risks they might not take otherwise. "If money clouds your judgment, it's doing something that we would all consider unacceptable," says Scott Halpern, a senior fellow in the University of Pennsylvania's department of bioethics. Second, money may be a stronger incentive for the poor than for the wealthy, putting the disadvantaged at even higher risk.

Halpern and his colleagues decided to test those theoretical concerns. They asked 126 patients with mild to moderate hypertension how they felt ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies